An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
An Open-Label, Single-Arm, Multiple-Dose, Phase 3 Safety and Efficacy Study of Cebranopadol in Participants With Moderate to Severe Acute Pain With Surgical or Non-Surgical Origin
- Pain
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Adneuris Therapeutics, Inc.
- Enrolment target
- 160
- Started
- September 2026
- Main results due
- January 2027
- Study sites
- 15
- Registry updated
- 28 September 2026
Can you take part?
- Ages 18 years to 75 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Adults 18 to 75 years of age. * Able to provide informed consent. * Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition. * Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment. * Willing and able to comply with study requirements Exclusion Criteria: * Chronic pain condition that requires ongoing pain medication. * Significant medical or psychiatric condition that could affect participation or study results. * History of substance use disorder or misuse of alcohol or drugs. * Current use of medications that may interfere with the study drug or pain assessments. * Known allergy or intolerance to cebranopadol or permitted rescue pain medications. * Pregnant or breastfeeding. * Participation in another clinical trial or receipt of an investigational drug within the protocol-defined period before study entry. * Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study assessments.
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.
Study sites(15)
Adneuris Site 001115
Phoenix, Arizona, United States
Not yet recruiting
Adneuris Site 001118
Riverside, California, United States
Not yet recruiting
Adneuris Site 001119
Longmont, Colorado, United States
Not yet recruiting
Adneuris Site 001122
Savannah, Georgia, United States
Not yet recruiting
Adneuris Site 001123
O'Fallon, Illinois, United States
Not yet recruiting
Adneuris Site 001125
Annapolis, Maryland, United States
Not yet recruiting
Adneuris Site 001120
Oradell, New Jersey, United States
Not yet recruiting
Adneuris Site 001124
Tulsa, Oklahoma, United States
Not yet recruiting
Adneuris Site 001110
Bellaire, Texas, United States
Not yet recruiting
Adneuris Site 001117
Forney, Texas, United States
Not yet recruiting
Adneuris Site 001104
McAllen, Texas, United States
Recruiting
Adneuris Site 001116
Plano, Texas, United States
Not yet recruiting
Adneuris Site 001111
San Antonio, Texas, United States
Not yet recruiting
Adneuris Site 001121
San Antonio, Texas, United States
Not yet recruiting
Adneuris Site 001101
Salt Lake City, Utah, United States
Not yet recruiting
Showing 15 of 15 sites. 1 of the 15 sites on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07845071. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me